Econazole
JFDA label: Eco-Cure Vaginal Ovule
Mechanism of Action
Alters fungal cell wall membrane permeability; may interfere with RNA and protein synthesis, and lipid metabolism
Indications
Approved
- Cream
- Foam
- Fungal infection
Contraindications
Source: Lexicomp
- Cream: Hypersensitivity to econazole or any component of the formulation Foam: There are no contraindications listed in the manufacturer’s labeling. Documentation of allergenic cross-reactivity for imidazole antifungals is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty Absolute
Adverse Reactions
Other (4)
Common Dermatologic: Burning sensation of skin · erythema · pruritus · stinging of the skin
Dosing
Source: Lexicomp
Warnings & Precautions
Source: Lexicomp
Irritation
Discontinue if sensitivity or irritation occurs. Dosage form specific issues:
Foam
Avoid heat, flame, and smoking during and immediately following application; topical foam is flammable. Other warnings/precautions:
Appropriate use
For topical use only; avoid contact with eyes, mouth, nose, or other mucous membranes
Pregnancy & Lactation
Pregnancy
Adverse events were observed in some animal reproduction studies. The manufacturer recommends avoiding use during pregnancy, especially during the first trimester.
Lactation
It is not known if econazole is excreted in breast milk. The manufacturer recommends that caution be exercised when administering econazole to nursing women.
Monitoring
| Clinical pearl | Reassess diagnosis if no clinical improvement after completion of treatment course. |
|---|
Chemistry & Properties
| Formula | C18H15Cl3N2O |
|---|---|
| Molecular weight | 381.69 g/mol |
| IUPAC name | 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole |
| CAS | 27220-47-9 |
| PubChem CID | 3198 |
| InChIKey | LEZWWPYKPKIXLL-UHFFFAOYSA-N |
| logP | 5.8 (XLogP 5.3) |
| Polar surface area | 27.05 Ų |
| H-bond acceptors / donors | 3 / 0 |
| Drug-likeness (QED) | 0.54 |
| Lipinski violations | 1 |
SMILES
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1Biology & Pharmacokinetics
Pharmacokinetics
| BBB penetrant | No |
|---|
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP1A2 | Inhibitor | IC₅₀ 0.3000000000000001 µM |
| CYP1A2 | Substrate | — |
| CYP2B6 | Inhibitor | — |
| CYP2C19 | Inhibitor | IC₅₀ 0.040000000000000015 µM |
| CYP2C8 | Inhibitor | — |
| CYP2C9 | Inhibitor | IC₅₀ 0.20000000000000004 µM |
| CYP2D6 | Inhibitor | IC₅₀ 0.40000000000000013 µM |
| CYP3A4 | Inhibitor | IC₅₀ 0.20996518697290756 µM |
| CYP3A4 | Substrate | — |
Receptor binding (top 2)
| Target | Action | Affinity |
|---|---|---|
| CYP8B1 (CYP8B1) | Inhibitor | pKd 7.2 |
| CYP8B1 (CYP8B1) | Inhibitor | pIC50 6.1 |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (10)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Ecorex Plus Cream | Cream 1 %, 0.1 % | 15 g tube pack varies | Hayat Pharmaceutical Industries CO.PLC/JORDAN | 1.690 |
| Ecorex Cream | Cream 1 % | 30 g tube pack varies | Hayat Pharmaceutical Industries CO.PLC/JORDAN | 2.000 |
| Eco-Cure Vaginal Ovule | Vaginal 150 mg | 3 Vaginal Ovules | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 2.250 |
| Ecorex ovules | Ovule 150 mg | 3 | Hayat Pharmaceutical Industries CO.PLC/JORDAN | 2.610 |
| Ecomi Ovules | Vaginal 150 mg | 3 Ovules | Kurdi Drug Store | 2.910 |
| Ecorex Plus Cream | Cream 1 %, 0.1 % | 30 g tube pack varies | Hayat Pharmaceutical Industries CO.PLC/JORDAN | 3.210 |
| Gyno-Pevaryl Depot | Tablet 150 mg | 2 tab | Shawi & Rushedat Drug Store | 3.460 |
| Ecorex vaginal Cream | Cream 1 % | 78 gm pack varies | Hayat Pharmaceutical Industries CO.PLC/JORDAN | 5.480 |
| Pevaryl Lipogel | Gel 1 % | 15 mg | Ninos Drug Store | 6.680 |
| Gyno-Pevaryl 50 Vag Ovules | Ovule 50 mg | 15 | Ninos Drug Store | 13.380 |